↓ Skip to main content

Dove Medical Press

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Overview of attention for article published in International Journal of Nanomedicine, April 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#19 of 3,919)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
10 news outlets
blogs
1 blog
patent
55 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
654 Dimensions

Readers on

mendeley
732 Mendeley
Title
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Published in
International Journal of Nanomedicine, April 2009
DOI 10.2147/ijn.s3061
Pubmed ID
Authors

Silverio Tomao

Abstract

Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 732 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 4 <1%
United States 3 <1%
Netherlands 2 <1%
Poland 2 <1%
France 1 <1%
Lithuania 1 <1%
Austria 1 <1%
Slovenia 1 <1%
Germany 1 <1%
Other 0 0%
Unknown 716 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 155 21%
Student > Master 100 14%
Researcher 86 12%
Student > Bachelor 69 9%
Student > Doctoral Student 45 6%
Other 99 14%
Unknown 178 24%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 107 15%
Chemistry 105 14%
Agricultural and Biological Sciences 90 12%
Biochemistry, Genetics and Molecular Biology 84 11%
Medicine and Dentistry 51 7%
Other 106 14%
Unknown 189 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 87. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2023.
All research outputs
#438,758
of 23,804,991 outputs
Outputs from International Journal of Nanomedicine
#19
of 3,919 outputs
Outputs of similar age
#935
of 96,108 outputs
Outputs of similar age from International Journal of Nanomedicine
#1
of 8 outputs
Altmetric has tracked 23,804,991 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,919 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,108 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them